✦ LIBER ✦

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

✍ Scribed by Claire F. Verschraegen; Andrzej P. Kudelka; Wei Hu; Monique Vincent; John J. Kayanagh; Evelyne Loyer; Luc Bastien; A. Duggal; R. De Jager

Book ID: 110611295
Publisher: Springer
Year: 2004
Tongue: English
Weight: 736 KB
Volume: 53
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf02665346

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Intravenous DX-8951f i

Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan

✍ C. F. VERSCHRAEGEN; C. LEVENBACK; M. VINCENT; J. WOLF; M. BEVERS; E. LOYER; A. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

A Phase II study of intravenous exatecan

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi

A Phase II Study of Intravenous Exatecan

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

✍ Melanie E. Royce; Eric K. Rowinsky; Paulo M. Hoff; John Coyle; Robert DeJager; R 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 99 KB